GlassScriptPhysician profile
Mary G Murphy
NPI 1699116855
$4,018.82
in general payments reported to CMS, 2019-2025
35 companies · $316 in 2025
The $316 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $662 · 2022: $1,294 · 2023: $985 · 2024: $761 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,063.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,062.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $910.63 | 2021-2023 | Austedo |
| Abbott Laboratories | $510.55 | 2023-2024 | Proclaim, Octrode |
| Abbvie INC. | $473.90 | 2021-2025 | |
| Medtronic, INC. | $323.12 | 2022-2025 | Intellis Adaptivestim, Inceptiv |
| Collegium Pharmaceutical, INC. | $213.71 | 2022-2025 | Xtampza, Belbuca, Nucynta |
| Lundbeck LLC | $184.82 | 2022-2025 | Vyepti |
| Lilly USA, LLC | $149.35 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $124.63 | 2021 | |
| Pfizer INC. | $116.90 | 2023-2024 | |
| Averitas Pharma INC. | $84.60 | 2024-2025 | Qutenza |
| Relievant Medsystems, INC. | $70.48 | 2023 | Intracept |
| Emd Serono, INC. | $66.89 | 2022 | |
| Vertos Medical, INC. | $65.54 | 2024 | Mild Device Kit |
| Novartis Pharmaceuticals Corporation | $63.55 | 2022-2023 | |
| Novo Nordisk INC | $62.66 | 2023 | Wegovy |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $58.72 | 2021-2022 | |
| Boston Scientific Corporation | $56.10 | 2024-2025 | Intracept |
| Valinor Pharma, LLC | $55.49 | 2023-2024 | Movantik |
| Vertex Pharmaceuticals Incorporated | $50.86 | 2024-2025 | |
| Merz Pharmaceuticals, LLC | $41.14 | 2023 | Xeomin |
| Alexion Pharmaceuticals, INC. | $36.97 | 2021-2022 | |
| Harmony Biosciences LLC | $33.46 | 2022 | |
| Eisai INC. | $33.33 | 2022 | |
| Mml US, INC. | $33.29 | 2025 | Reactiv8 |
| Acadia Pharmaceuticals INC | $26.95 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.01 | 2022 | |
| Kyowa Kirin, INC. | $21.09 | 2021 | |
| Jazz Pharmaceuticals INC. | $21.07 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.98 | 2025 | Relistor |
| Ferring Pharmaceuticals INC. | $15.68 | 2025 | Adstiladrin |
| Biogen, INC. | $15.65 | 2022 | |
| Celgene Corporation | $15.01 | 2022 | |
| Genzyme Corporation | $14.77 | 2022 | |
| Ge Healthcare | $14.53 | 2022 | |
| Nevro Corp. | $13.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.